Kim Treanor

Kim Treanor

  • Articles: 23

Do US Patent Incentives Need To Change To Get The ‘Cancer Moonshot’ Off The Ground?

In December, the United States Congress passed a bill with a monumental goal: engaging the private sector to work with each other, and with the government, to develop new treatments for cancer. The mechanics of cancer research, however, may require fundamental changes to our patent system if the initiative is to be successful. Intellectual Property Watch recently sat down with Jacob Sherkow, associate professor of law and affiliated faculty at the Innovation Center for Law and Technology at New York University Law School, to discuss challenges to overcome to get the Moonshot off the ground.

USTR Issues 2017 Trade Policy Review, Listing IPR Priorities

The Office of the United States Trade Representative today released its 2017 trade policy agenda. The report includes numerous references to intellectual property rights, mainly focused on enforcement, plans for multilateral discussions on IPR and trade, and promises of an aggressive stance on geographical indications. But overall it is short on overall details about what's to come with the new administration.

A Look At Latest Figures On R&D For Neglected Diseases

Financing for research and development into so-called neglected diseases – those predominantly affecting lower-income populations – rose recently mainly due to the Ebola outbreak, and private sector contributions represent a bigger share, according to the latest available data from a Gates Foundation-supported database.

BIO Investor Conference: New Technologies, Old Pricing Systems, And Insurance Payers In The US

NEW YORK -- At a recent biotechnology investors event in the United States, the prospect of repeal or redesign of the Affordable Care Act, the president’s recent remarks on the prospect of Medicare negotiating prices directly with pharmaceutical corporations, and the public debate surrounding high priced medicines, meant few panels were immune from questions of affordability, access and payment.

Groups Seek Assurance Of Affordable Zika Vaccine From US Army Exclusive Licence

A range of civil society organisations have issued a public statement opposing the United States Army’s proposed grant of an exclusive licence on technology necessary to produce a Zika vaccine to French pharmaceutical company Sanofi. The letter cites concerns that the exclusive licence might violate US law and could lead to high priced medicines as consumers buy back taxpayer-funded research.